ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil) prnewswire
September 28, 2021NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage, biopharmaceutical company, today announced top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 ?who were treated with ZYESAMI?. -
NRx Pharmaceuticals Presents Evidence ZYESAMI? (aviptadil) Helps Prevent "Cytokine Storm" in Patients with COVID-19 prnewswire
July 20, 2021The presentation identifies a statistically significant effect of ZYESAMI? (aviptadil) in preventing the sharp rise in cytokines, commonly associated with mortality in patients with COVID-19.
Pharma Sources Insight January 2025
